Teva to resume anesthesia marketing due to shortage

Teva was in the past subject to many suits after patients treated with Propofol contracted Hepatitis C.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) will resume marketing of its anesthesia, Propofol, by the end of February, to help ease a shortage in the US. Teva discontinued its involvement with propofol in 2010.

Germany's Fresenius SE & Co. KGaA has also increased propofol production and the US Food and Drug Administration (FDA) will continue imports of a similar drug Propoven. The ASA is working with the FDA to mitigate and prevent further shortages.

In 2010 and 2011 Teva was forced to pay over $800 million compensation in suits and out of court settlements to patients suffering Hepatitis C from contaminated Propofol. Teva claimed the fault was with negligent use by doctors. As a result of these suits and an FDA warning about problems in its California production plant, the company stopped producing the anesthesia in May 2010.

Propofol was also reportedly found in the home of singer Michael Jackson when he died but it was not part of a contaminated batch that had recently been pulled from shelves by Teva.

Published by Globes [online], Israel business news - www.globes-online.com - on January 29, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס